CRVO - NASDAQ
CervoMed Inc.
$5.50
-0.36%CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
At a Glance
Live Snapshotcrvo
Total Equity
Last Annual Value
39.20M
3-Year CAGR
4%
5-Year CAGR
14%
10-Year CAGR
%
CervoMed Inc. Competitors Analysis of Total Equity
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
CervoMed Inc. NASDAQ:CRVO | 39.20M | 74.5% | 2.3% | 15.6% | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | -15.94M | N/A | N/A | N/A | |
 Fortress Biotech, Inc. NASDAQ:FBIO | 62.18M | 239.6% | -22.7% | -2.8% | |
 OS Therapies Incorporated NYSE:OSTX | 811.49K | N/A | N/A | N/A | |
 Adicet Bio, Inc. NASDAQ:ACET | 159.21M | -2.2% | -12.1% | -6.3% | |
 Clene Inc. NASDAQ:CLNN | -17.59M | N/A | N/A | N/A | |
 Werewolf Therapeutics, Inc. NASDAQ:HOWL | 24.80M | -39.4% | -30.5% | N/A | |
 MindWalk Holdings Corp. NASDAQ:HYFT | 23.63M | -25.8% | -16.1% | 38.5% | |
 Immix Biopharma, Inc. NASDAQ:IMMX | 93.80M | 79.6% | 39.1% | N/A | |
 PMV Pharmaceuticals, Inc. NASDAQ:PMVP | 104.71M | -22.6% | -19.4% | N/A | |
 Vaxart, Inc. NASDAQ:VXRT | 87.80M | 14.9% | -14.1% | 16.7% |
CervoMed Inc. Fair Value Envelope
Related Guides
Continue your CRVO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.